Switching Blood Thinners After Stent Placement
Part of Heart & circulation clinical trials.
This study compares two ways to manage blood thinners after a stent. It tests whether switching from stronger drugs (prasugrel or ticagrelor) to clopidogrel is safe and effective for long-term heart protection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stent placed in a heart artery and are now taking low-dose aspirin plus either prasugrel or ticagrelor.
- If the stent was for a heart attack, at least 90 days must have passed since the procedure.
- If the stent was for stable chest pain, at least 30 days must have passed.
- You must be 18 years or older.
- You cannot have had a stent blockage before, be on blood thinners like warfarin or apixaban, or have low platelets or hemoglobin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests switching from a standard blood thinner (clopidogrel) to a lower dose of a stronger one (prasugrel) in people who have had a stent placed and are at high risk for both bleeding and heart problems. The goal is to see if the switch better prevents clots while keeping bleeding risks low.
This trial is testing whether lowering the dose of your current blood thinner or switching to a different one (clopidogrel) is safer and works just as well after you've had a stent placed. It's designed for people who are already on two blood thinners and are doing well.
This trial tests if people who have been on two blood thinners (aspirin plus prasugrel or ticagrelor) for at least 90 days after getting a heart stent can safely switch to just one of those blood thinners. It aims to see if taking only one pill is as safe and effective as taking two.
This trial studies ways to reduce bleeding in people after a stent procedure (PCI) who have been taking two anti-platelet medicines (aspirin plus prasugrel or ticagrelor) for a set amount of time. It may help find a safer plan for preventing blood clots while lowering bleeding risk.
This trial tests whether a lower dose of the blood thinner ticagrelor works better than clopidogrel in people with stable coronary artery disease who are getting a planned stent. It aims to find which drug is safer and more effective for preventing future heart problems.
This trial studies whether changing the timing and type of blood-thinner tablets after a heart stent is as safe and effective as continuing the same plan. It may help some people by simplifying treatment while preventing dangerous clotting after a coronary procedure.
Hear when a new Coronary Arterial Disease (CAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.